Altium Capital Management LLC Boosts Stock Position in RxSight, Inc. (NASDAQ:RXST)

Market Beat
2025.04.19 11:44
portai
I'm PortAI, I can summarize articles.

Altium Capital Management LLC increased its stake in RxSight, Inc. (NASDAQ:RXST) by 154.5% in Q4, owning 285,000 shares after acquiring 173,000 additional shares. The stock represents 2.8% of Altium's holdings. Other hedge funds also increased their positions. Insider sales were reported, with directors selling shares at varying prices. Analysts have mixed ratings on RxSight, with price targets ranging from $16.00 to $43.00. The stock opened at $14.52, with a market cap of $587.93 million and a 52-week range of $13.50 to $66.54.

Altium Capital Management LLC lifted its stake in RxSight, Inc. (NASDAQ:RXST - Free Report) by 154.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 285,000 shares of the company's stock after acquiring an additional 173,000 shares during the period. RxSight makes up about 2.8% of Altium Capital Management LLC's holdings, making the stock its 11th largest holding. Altium Capital Management LLC owned 0.71% of RxSight worth $9,798,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Private Trust Co. NA bought a new position in shares of RxSight in the fourth quarter valued at approximately $34,000. Arcadia Investment Management Corp MI bought a new position in RxSight in the 4th quarter valued at $46,000. Harbor Investment Advisory LLC bought a new position in RxSight in the 4th quarter valued at $52,000. Global Retirement Partners LLC purchased a new position in shares of RxSight during the 4th quarter valued at $69,000. Finally, KBC Group NV increased its holdings in shares of RxSight by 71.0% in the fourth quarter. KBC Group NV now owns 2,107 shares of the company's stock worth $72,000 after purchasing an additional 875 shares during the period. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Tamara Fountain sold 7,000 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total value of $179,970.00. Following the sale, the director now directly owns 24,793 shares of the company's stock, valued at $637,428.03. The trade was a 22.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Shweta Maniar sold 3,519 shares of the company's stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.87, for a total value of $108,631.53. Following the completion of the sale, the director now owns 7,383 shares in the company, valued at $227,913.21. The trade was a 32.28 % decrease in their position. The disclosure for this sale can be found here. 9.36% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Bank of America reissued an "underperform" rating and set a $22.00 price objective (down previously from $36.00) on shares of RxSight in a research note on Thursday, April 3rd. Stifel Nicolaus cut their price objective on RxSight from $33.00 to $28.00 and set a "hold" rating for the company in a report on Wednesday, March 19th. Needham & Company LLC restated a "buy" rating and issued a $43.00 price objective on shares of RxSight in a research report on Thursday, April 3rd. JPMorgan Chase & Co. reiterated an "underweight" rating and set a $17.00 target price (down from $40.00) on shares of RxSight in a research report on Friday, April 4th. Finally, UBS Group lowered shares of RxSight from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $45.00 to $16.00 in a report on Wednesday, April 9th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $37.60.

Check Out Our Latest Research Report on RXST

RxSight Stock Down 0.7 %

Shares of RxSight stock opened at $14.52 on Thursday. The company has a market cap of $587.93 million, a PE ratio of -17.49 and a beta of 1.26. The business has a 50 day moving average of $24.48 and a 200 day moving average of $35.60. RxSight, Inc. has a 52 week low of $13.50 and a 52 week high of $66.54.

RxSight (NASDAQ:RXST - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.10 by ($0.25). RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The company had revenue of $40.21 million during the quarter, compared to analysts' expectations of $40.23 million. On average, research analysts anticipate that RxSight, Inc. will post -0.7 earnings per share for the current year.

About RxSight

(Free Report)

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Featured Stories

  • Five stocks we like better than RxSight
  • What Are Some of the Best Large-Cap Stocks to Buy?
  • 3 Reasons to Like the Look of Amazon Ahead of Earnings
  • Stock Sentiment Analysis: How it Works
  • Tariff-Resistant Abbott Laboratories on Track for New Highs
  • 10 Best Airline Stocks to Buy
  • United Airlines Is in Reversal—If the Economy Doesn’t Stall

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in RxSight Right Now?

Before you consider RxSight, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.

While RxSight currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.